** Vaccine maker Moderna's MRNA.O shares fall 2.2% to $31.30 premarket
** Co reports Q4 loss of $2.91/share vs analyst est. of loss of $2.68/share, as per data compiled by LSEG
** MRNA posts Q4 revenue of $966 million, beating analysts' est. of $942.84 million
** Co says the decrease was mostly due to the earlier launch of its updated COVID-19 vaccine in the U.S., which shifted sales into the third quarter, but also due to lower international sales
** Stock fell ~67% in the last 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。